CIK 0001237831 · Large accelerated filer
GLOBUS MEDICAL INC
Sign in to watch- Ticker
- GMED
- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043744954
- Phone
- 610-930-1800
- Business address
- 2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA, 19403
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,970,014
- in 4 filings, $425K under 10b5-1 plans
Net −$7,970,014. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-05 | Davidar David D Director | Option exercise · Stock Option (Right to Buy Class A Common Stock) | −25,000 | 0 | ||
| 2026-06-04 | RHOADS ANN D Director | Option exercise | +25,000 | $26.27 | $657K | 40,384 |
| 2026-06-04 | RHOADS ANN D Director | Option exercise · Stock Option (Right to Buy Class A Common Stock) | −25,000 | 0 | ||
| 2026-02-25 | Huller Kelly EVP, GC, Corporate Secretary | Option exercise 10b5-1 | +20,000 | $43.58 | $872K | 20,000 |
| 2026-02-25 | Huller Kelly EVP, GC, Corporate Secretary | Sale 10b5-1 | −20,000 | $94.50 | $1.9M | 0 |
| 2026-02-25 | Huller Kelly EVP, GC, Corporate Secretary | Option exercise · Stock Option (Right to Buy Class A Common Stock) 10b5-1 | −20,000 | 20,000 | ||
| 2026-02-12 | Huller Kelly EVP, GC, Corporate Secretary | Option exercise 10b5-1 | +10,000 | $45.64 | $456K | 10,000 |
| 2026-02-12 | Huller Kelly EVP, GC, Corporate Secretary | Sale 10b5-1 | −10,000 | $87.67 | $877K | 0 |
| 2026-02-12 | Huller Kelly EVP, GC, Corporate Secretary | Option exercise · Stock Option (Right to Buy Class A Common Stock) 10b5-1 | −10,000 | 0 | ||
| 2026-01-21 | Norwalk Leslie V Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +15,000 | 15,000 | ||
| 2026-01-21 | Pfeil Keith W President, CEO | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +100,000 | 100,000 | ||
| 2026-01-21 | Kline Kyle Senior Vice President, CFO | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +30,000 | 30,000 | ||
| 2026-01-21 | Paul David C Executive Chairman | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +100,000 | 100,000 | ||
| 2026-01-21 | Douglas Robert Andrew Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +15,000 | 15,000 | ||
| 2026-01-21 | Lemaitre Dan Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +15,000 | 15,000 | ||
| 2026-01-21 | RHOADS ANN D Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +15,000 | 15,000 | ||
| 2026-01-21 | TOBIN JAMES R Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +15,000 | 15,000 | ||
| 2026-01-21 | ZARRILLI STEPHEN T Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +15,000 | 15,000 | ||
| 2026-01-21 | DeFord John A Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +15,000 | 15,000 | ||
| 2026-01-21 | Wolterman Dan Director | Grant or award · Stock Option (Right to Buy Class A Common Stock) | +15,000 | 15,000 |
Page 2 of 10 · 200 trades